Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allos Therapeutics has reported that a trial of its cancer drug PDX can go ahead after the Data Monitoring Committee conducted an interim analysis of safety data and recommended that the study continue.
Subscribe to our email newsletter
The committee evaluated the first ten patients enrolled to the phase II trial of PDX in patients with relapsed or refractory peripheral T-cell lymphoma who had completed one cycle of treatment with PDX, and has recommended that the trial continue. No major patient safety concerns were identified by the DMC.
Paul Berns, president and CEO of Allos, said: “We are pleased with the DMC’s recommendation and are grateful for the support received from our employees, investigators and patients who enabled us to reach this milestone.”
In accordance with the study’s design, an interim analysis of efficacy data will be conducted after 35 patients have completed one cycle of treatment with PDX, which is currently expected to occur in the second half of 2007.